Nilotinib Stada (Nilotinib)

Nilotinib targets the BCR‑ABL tyrosine‑kinase pathway and is employed in chronic myeloid leukemia therapy.

• Chronic myeloid leukemia (chronic phase): Reduces malignant cell proliferation and improves survival in adult patients.
• Chronic myeloid leukemia (accelerated phase): Helps achieve hematologic and cytogenetic responses when disease progresses.
• Chronic myeloid leukemia (blast phase): Provides a therapeutic option for patients with advanced disease resistant to prior therapy.

• Nilotinib selectively inhibits the BCR‑ABL tyrosine kinase, a fusion protein that drives uncontrolled cell growth in Philadelphia chromosome‑positive leukemic cells. By binding to the ATP‑binding site of the kinase, it blocks downstream signaling pathways responsible for proliferation, survival, and migration of malignant clones, thereby restoring normal hematopoiesis.

Adverse reactions may vary in frequency and severity.

Common Side Effects

• Rash: mild to moderate skin eruptions.
• Nausea: occasional gastrointestinal upset.
• Diarrhea: loose stools, often self‑limiting.
• Fatigue: generalized tiredness.
• Elevated liver enzymes: mild transaminase increase.
• Myalgia: muscle aches.

Serious or Rare Side Effects

• Cardiovascular events: including arterial occlusion or ischemia.
• Pancreatitis: inflammation of the pancreas.
• Severe hepatotoxicity: marked liver injury.
• QT interval prolongation: potential cardiac arrhythmia.
• Severe skin reactions: such as Stevens‑Johnson syndrome.
• Hyperglycemia: significant rise in blood glucose levels.

Patients should be monitored for specific safety concerns before and during therapy.

• Cardiac assessment: evaluate baseline cardiovascular risk and monitor for ischemic events.
• Hepatic function: check liver enzymes regularly and adjust therapy if significant elevation occurs.
• Electrolyte balance: monitor potassium and magnesium to reduce QT prolongation risk.
• Blood glucose: assess glucose levels, especially in diabetic patients.
• Drug interactions: review concomitant medications that may affect metabolism.
• Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture and direct sunlight.

Nilotinib may interact with several drug classes, requiring careful management.

Major Interactions (Avoid)

• Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): markedly reduce nilotinib exposure.
• Proton‑pump inhibitors (e.g., omeprazole) taken with nilotinib: decrease absorption and efficacy.
• QT‑prolonging agents (e.g., certain antiarrhythmics): increase risk of serious cardiac arrhythmias.

Moderate Interactions (Monitor Closely)

• Anticoagulants (e.g., warfarin): may require INR monitoring.
• Statins metabolized by CYP3A4 (e.g., simvastatin): risk of increased statin levels.
• Antidiabetic drugs: nilotinib can affect glucose control, requiring dose adjustments.